4-(4-chlorophenylamino)-7-methoxyquinazolin-6-ol | 808762-44-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(4-chlorophenylamino)-7-methoxyquinazolin-6-ol
• 英文别名: 4-(4-Chloro-phenylamino)-7-methoxy-quinazolin-6-ol；4-(4-chloroanilino)-7-methoxyquinazolin-6-ol
• CAS: 808762-44-9
• 化学式: C₁₅H₁₂ClN₃O₂
• 分子量: 301.732
• InChiKey: CEHGOSCODWMMSS-UHFFFAOYSA-N

物化性质

• 沸点：
  486.7±45.0 °C(Predicted)
• 密度：
  1.433±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  67.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(4-chlorophenylamino)-7-methoxyquinazolin-6-ol 在 羟胺 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 7-(4-(4-chlorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC

  摘要：

  A single agent that simultaneously inhibits multiple targets may offer greater therapeutic benefits in cancer than single-acting agents through interference with multiple pathways and potential synergistic action. In this work, a series of hybrids bearing N-phenylquinazolin-4-amine and hydroxamic acid moieties were designed and identified as dual VEGFR-2/HDAC inhibitors. Compound 6fd exhibited the most potent inhibitory activity against HDAC with IC50 of 2.2 nM and strong inhibitory effect against VEGFR-2 with IC50 of 74 nM. It also showed the most potent inhibitory activity against a human breast cancer cell line MCF-7 with IC50 of 0.85 mu M. Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the active binding sites of VEGFR-2 and HDLP ((Histone Deacetylase-Like Protein), which demonstrates that compound 6fd is a potential agent for cancer therapy deserving further researching. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.12.033
• 作为产物：
  描述：

  3,4-二氢-7-甲氧基-4-氧代喹唑啉-6-醇乙酸酯 在 ammonium hydroxide 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 1.5h， 生成 4-(4-chlorophenylamino)-7-methoxyquinazolin-6-ol
  参考文献：
  名称：

  含苯并噻唑结构的4,6,7-三取代喹唑啉衍生物的设计、合成及抗肿瘤活性评价

  摘要：

  设计、合成了一系列含有苯并噻唑部分的新型4,6,7-三取代喹唑啉衍生物，并使用MTT法评估了它们对四种人类癌细胞（PC-3、MGC-803、A549和Eca-109）的抗肿瘤活性。其中，化合物11k对PC-3细胞表现出最强的细胞毒性（IC 50  = 5.59 ± 0.78 μM）。化合物11k还显着抑制PC-3细胞的集落形成和迁移。同时，化合物11k诱导细胞周期停滞在S期和细胞凋亡，并增加细胞内活性氧的积累。所有研究结果表明化合物11k可能是针对前列腺癌细胞的抗肿瘤药物的一种有价值的先导化合物。

  DOI：

  10.1007/s00044-023-03117-8

文献信息

• Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors
  作者：Bin Zhang、Zhikun Liu、Shengjin Xia、Qingqing Liu、Shaohua Gou

  DOI：10.1016/j.ejmech.2021.113300

  日期：2021.4

  especially dual-target, drug design has become a popular research field for cancer treatment. Development of small molecule dual-target inhibitors through hybridization strategy can provide highly potent and selective anticancer agents. In this study, three series of quinazoline derivatives bearing a benzene-sulfonamide moiety were designed and synthesized as dual EGFR/CAIX inhibitors. All the synthesized

  多靶标，尤其是双靶标的药物设计已成为癌症治疗的流行研究领域。通过杂交策略开发小分子双靶标抑制剂可提供高度有效和选择性的抗癌药。在这项研究中，设计并合成了三个系列的带有苯磺酰胺部分的喹唑啉衍生物，作为双重EGFR / CAIX抑制剂。评价了所有合成的化合物对表皮样癌（A431）和非小细胞肺癌（A549和H1975）细胞系的抵抗，这些细胞系显示出弱至有效的抗癌活性。特别是，化合物8v成为对抗突变型H1975细胞最有效的衍生物，该突变型细胞与osimertinib具有可比的活性。重要的是8v在缺氧条件下，对H1975细胞具有比osimertinib更强的抗增殖活性。激酶抑制研究表明8v对EGFR T790M酶具有优异的抑制作用，其效力是吉非替尼的41倍，几乎与奥西替尼相当。机理研究表明8v在H1975细胞中显示出与乙酰唑胺相当的CAIX抑制作用，并显着抑制p-EGFR及其下游p-AKT和p-ER
• Synthesis of several new quinazolin-4-amines containing <i>p</i>-toluenesulfonate moiety
  作者：Zhi-qiang Cai、Zheng-sheng Jin、De-qiang Zheng、Ling Hou、Guan-wang Huang、Jun-qiang Tian、Guo-jiang Wang

  DOI：10.3184/174751916x14725679922221

  日期：2016.9

  A series of novel quinazolin-4-amine derivatives containing p-toluenesulfonate moiety have been synthesised through the reaction of 4-chloro-7-methoxyquinazolin-6-yl acetate with substituted anilines in toluene solution at 90 °C. Further treatment of the synthesised compound with ammonium hydroxide gave the corresponding substituted quinazoline derivatives which were subsequently processed through

  通过 4-氯-7-甲氧基喹唑啉-6-基乙酸酯与取代苯胺在 90 °C 的甲苯溶液中反应，合成了一系列含有对甲苯磺酸酯部分的新型喹唑啉-4-胺衍生物。用氢氧化铵进一步处理合成的化合物，得到相应的取代喹唑啉衍生物，随后通过磺酰基反应将其加工成含有 DMF 中对甲苯磺酸盐部分的喹唑啉-4-胺。它们的结构是通过元素分析、IR 和 1H NMR 光谱确定的。
• Phenalene derivatives
  申请人：——

  公开号：US20040254205A1

  公开（公告）日：2004-12-16

  Novel 1,3,4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives are disclosed. These compounds inhibit epidermal growth factor receptor (“EGFR”) tyrosine kinase. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful, inter alia, in the treatment or control of cancer, in particular solid tumors. This invention also relates to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors.

  揭示了小说1,3,4-三氮杂菲和1,3,4,6-四氮杂菲衍生物。这些化合物抑制表皮生长因子受体（“EGFR”）酪氨酸激酶。这些化合物及其药学上可接受的盐和酯具有抗增殖活性，并且在治疗或控制癌症，特别是固体肿瘤方面非常有用。该发明还涉及含有这些化合物的药物组合物以及治疗或控制癌症的方法，尤其是治疗或控制乳腺、肺部、结肠和前列腺肿瘤。
• Design, synthesis and anti-tumor activity evaluation of 4,6,7-substitute quinazoline derivatives
  作者：Honglin Dai、Xiaojie Si、Hao Wang、Lingling Chi、Chao Gao、Zhengjie Wang、Limin Liu、Zhuo Qian、Yu Ke、Qiurong Zhang、Hongmin Liu

  DOI：10.1007/s00044-022-02897-9

  日期：2022.8

  A series of novel 4,6,7-substituted quinazoline derivatives were designed, synthesized and evaluated for their antiproliferative activities against human cancer cell lines (PC-3, MGC-803, HGC-27, A549 and H1975). Among all the target compounds, compound 22s displayed the most potent anti-proliferative activity against MGC-803 cells in vitro. Further mechanism studies revealed that compound 22s could

  设计、合成了一系列新型 4,6,7-取代的喹唑啉衍生物，并评估了它们对人类癌细胞系（PC-3、MGC-803、HGC-27、A549 和 H1975）的抗增殖活性。在所有目标化合物中，化合物22s在体外对 MGC-803 细胞表现出最有效的抗增殖活性。进一步的机制研究表明，化合物22s可以明显抑制MGC-803细胞的集落形成和迁移。同时，化合物22s可诱导MGC-803细胞凋亡，诱导细胞周期停滞于G1期。总的来说，这些工作表明化合物22s可能是优化基于苯胺喹唑啉的抗肿瘤药物的有价值的解决方案。
• Ding, Hai-guan; Cai, Zhi-qiang; Hou, Ling, Journal of the Chemical Society of Pakistan, 2019, vol. 41, # 1, p. 186 - 190
  作者：Ding, Hai-guan、Cai, Zhi-qiang、Hou, Ling、Hu, Zhi-quan、Jin, Zheng-sheng、Xu, Di、Cao, Hui、Meng, Miao-miao、Xie, Yu-Hui、Zheng, De-qiang

  DOI：——

  日期：——